Track topics on Twitter Track topics that are important to you
Fresh off of striking a research deal with Ladenburg, Germany-based Heidelberg Pharma GmbH, Magenta Therapeutics secured $52 million.The funds will be used to advance Magenta's portfolio of bone marro...
Magenta Therapeutics Inc. and Heidelberg Pharma AG teamed up to discover and develop antibodies that improve bone marrow transplantation procedures for cancer patients.
Bastiano Sanna has been named CEO and president of Semma Therapeutics. Elizabeth Stoner, who has been serving as interim CEO, will remain as an advisor to the company. Sanna comes to Cambridge, MA-bas...
Magenta Therapeutics Inc. (curative stem cell transplantation) netted $93mm through its initial public offering of 6.67mm common shares at $15, the midpoint of its anticipated range.
Weeks after securing $52 million in a Series C financing, Magenta Therapeutics is eying the raising of $100 million in an initial public offering two years after it was launched by Third Rock Ventures...
Magenta Therapeutics' stem cell platform will be combined with Heidelberg Pharma's antibody-targeted amanitin conjugates plat -More-
Magenta Therapeutics, a biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced that chief ...
ALDEX GS™ Tablets
ALDEX GS DMTablets
Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...
To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.
Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...
The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...
Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System
The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...
The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...
This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...
Magenta Therapeutics is a biotechnology company developing therapeutics to revolutionize bone marrow transplant for patients with autoimmune diseases, blood cancers and genetic di...
Magenta Therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based dise...
Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...
We have published hundreds of Magenta Therapeutics, Inc. news stories on BioPortfolio along with dozens of Magenta Therapeutics, Inc. Clinical Trials and PubMed Articles about Magenta Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Magenta Therapeutics, Inc. Companies in our database. You can also find out about relevant Magenta Therapeutics, Inc. Drugs and Medications on this site too.